Skip to main content

Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CEO Albert Bourla said Pfizer is staring down an expected loss of up to $18 billion in revenue from 2025 through 2030 as patent protections expire.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.